ApoGen Biotechnologies Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 11
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $11M
Latest Deal Amount
  • Investors
  • 10

ApoGen Biotechnologies General Information

Description

Developer of a pharmaceutical and biotechnology company intended to focus on the development of a new class of therapeutics targeting drivers of cancer genomic mutation. The company's platform provides therapies that target key drivers of ongoing DNA mutation and tumor evolution, enabling doctors to break drug resistance in cancer treatment.

Contact Information

Website
www.apogenbiotech.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Primary Office
  • 2815 Eastlake Avenue East
  • Suite 300
  • Seattle, WA 98102
  • United States
+1 (206) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ApoGen Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 23-Aug-2018 $11M 0000 000.00 Completed Generating Revenue
1. Seed Round Completed Startup
To view ApoGen Biotechnologies’s complete valuation and funding history, request access »

ApoGen Biotechnologies Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A 0,000,000 00.000000 00 00 00 00 00.000
To view ApoGen Biotechnologies’s complete cap table history, request access »

ApoGen Biotechnologies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a pharmaceutical and biotechnology company intended to focus on the development of a new class of therapeut
Biotechnology
Seattle, WA
11 As of 2020
0000
00.00 0000-00-00
00000000000 0000

00000000

llamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in vo
000000000000000
Tokyo, Japan
0 As of 0000
000.00
0000000000 0 000.00

000000 0

citation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehend
0000000000000
South San Francisco, CA
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ApoGen Biotechnologies Competitors (42)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Anaeropharma Science Venture Capital-Backed Tokyo, Japan 0 000.00 0000000000 0 000.00
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
000000000000 Venture Capital-Backed Seattle, WA 00 000.00 00000000000 000.00
0000000 0000000000 Venture Capital-Backed Maastricht, Netherlands 00 000.00 0000000000 000.00
000000000 Venture Capital-Backed Gaithersburg, MD 00 000.00 00000000 000.00
You’re viewing 5 of 42 competitors. Get the full list »

ApoGen Biotechnologies Executive Team (4)

Name Title Board Seat Contact Info
Daniel Harki Ph.D Co-Founder
Reuben Harris Ph.D Co-Founder
Thong Le Chief Executive Officer & Board Member
John Santini Jr. Co-Founder & Board Member
To view ApoGen Biotechnologies’s complete executive team members history, request access »

ApoGen Biotechnologies Board Members (7)

Name Representing Role Since
Asish Xavier ApoGen Biotechnologies Board Member 000 0000
James Sullivan ApoGen Biotechnologies Board Member 000 0000
Joel Marcus ApoGen Biotechnologies Board Member 000 0000
John Santini Jr. Self Co-Founder & Board Member 000 0000
Johnston Erwin ApoGen Biotechnologies Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

ApoGen Biotechnologies Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ApoGen Biotechnologies Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
AbbVie Ventures Corporate Venture Capital Minority 000 0000 000000 0
Accelerator Life Science Partners Venture Capital Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
ARCH Venture Partners Venture Capital Minority 000 0000 000000 0
Eli Lilly Corporation Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial